А. Н. Махсон
Moscow City Oncology Hospital №62(RU)
Publications by Year
Research Areas
Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, Sarcoma Diagnosis and Treatment, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer(2010)404 cited
- → Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer(2009)341 cited
- → First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study(2012)260 cited
- → Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial(2012)212 cited
- → Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer(2013)139 cited
- → Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival(2012)122 cited
- → Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study(2009)116 cited
- → Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer(2008)110 cited
- → Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study(2007)101 cited
- → Development of a new G-CSF product based on biosimilarity assessment(2009)90 cited